Careful review of the literature and evaluation of the clinical trials reveals that the position of aspirin as an antithrombotic agent in orthopaedic patients is still not clear. Men who are more than 40 yr old, without a previous history of thromboembolic disease or venous surgery on the lower extremity, who are undergoing hip replacement, are the only group protected from pulmonary embolism by 600 milligrams of aspirin twice a day. These patients still have a relatively high (25%) incidence of deep venous thrombosis. There were, however, no patients treated with aspirin who had fatal pulmonary emboli in any of the studies reviewed. The decrease in pulmonary emboli in all patients, the absence of fatal emboli, and the low incidence of bleeding problems support the theory of the efficacy of aspirin.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Bone and Joint Surgery - Series A|
|State||Published - Jan 1 1980|
ASJC Scopus subject areas
- Orthopedics and Sports Medicine